Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alitretinoin in Severe Refractory Chronic Hand Dermatitis
NCT00309621Phase 3Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Apr 2006
- Primary completion
- Apr 2007
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of alitretinoin in chronic hand dermatitis (CHE), sponsored by Basilea Pharmaceutica. Primary endpoints: Safety, Adverse Events and 2 more. Started Apr 2006; status: completed.
02
Drugs
alitretinoin
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on NCT00309621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309621.